Drug Profile
Research programme: oral carfilzomib analogues - Onyx
Alternative Names: PR 924; PR-924 (LMP-7-selective peptide-ketoepoxide proteasome inhibitor); PR-928Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Onyx Pharmaceuticals
- Class Oligopeptides
- Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Multiple myeloma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral, Injection)
- 01 Oct 2013 Onyx Pharmaceuticals has been acquired by Amgen